May 7 (Reuters) - Bioporto A/S BIOPOR.CO :
* REG-BIOPORTO ANNOUNCES Q1 2020 REPORT
* Q1 REVENUE DKK 4.2 MILLION VERSUS DKK 5.5 MILLION YEAR
AGO
* Q1 EBIT LOSS DKK 16.4 MILLION VERSUS LOSS DKK 17.1
MILLION YEAR
AGO
* 2020 GUIDANCE MAINTAINED
* TIMELINE FOR FDA APPLICATION FOR NGAL TEST: BIOPORTO
PROJECTS
THAT COSTS RELATED TO CLINICAL TRIAL AS WELL AS SUBMISSION OF
FDA APPLICATION WILL BE POSTPONED TO SECOND HALF OF 2020.
Source text for Eikon: ID:nGNE62fXy5
Further company coverage: BIOPOR.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))